Moderna and Merck say their new mRNA vaccine, when combined with Keytruda, has shown promise in preventing the skin cancer ...

Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma ...

A vaccine has been shown to help keep melanoma, the deadliest form of skin cancer, from coming back in patients at higher ...

Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a ...

The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells ...

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved ...

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...

Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found. A Phase 3 trial found that adding the individualized ...

Adults at high risk of melanoma recurrence and spread were able to stay cancer-free with personalized vaccines made with mRNA ...

Merck and Moderna announced successful interim results of their personalized mRNA vaccine trial combined with Keytruda, ...